Search
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigationalthe FDA as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including
Products: EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL, EYLEA 40MG/ML SOLUTION FOR INJECTION IN PREFILLED SYRINGEDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Thiopental
go.drugbank.com/drugs/DB00599ApprovedInvestigationalVet approvedWithdrawnIt does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold.
Hydrogenated soybean oil
go.drugbank.com/drugs/DB11302ApprovedLinolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.
Crotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedThe final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.
N-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalN-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenou...
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate
Cabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigationalIt was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]
Products: XITACAB® 60MG/1.5ML (40MG/ML), JEVTANA 60mg CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION